In addition, reduced expression of SHP2 resulted in augmented radiosensitivity in glioma cells [91], suggesting that SHP2 has potential as a therapeutic target for GBM, even without oncogenic activation or overexpression. This evidence concerns the gene PTPN11 and glioma.